{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:12:38Z","timestamp":1788394358409,"version":"build-2803163510"},"reference-count":17,"publisher":"American Society of Consultant Pharmacists","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["sr care pharm"],"published-print":{"date-parts":[[2023,7,1]]},"abstract":"<jats:p>Prevalence of dementia continues to increase with limited pharmacotherapy options available. Acetylcholinesterase inhibitors remain a mainstay of treatment. The US FDA has approved three oral medications within this class\u2014 donepezil, galantamine, and rivastigmine. In 2022, the\n US Food and Drug Administration approved a novel patch formulation for donepezil that could be beneficial for patients with dysphagia as well as potentially decreasing the side effect burden. The purpose of this analysis is to review the efficacy, safety, tolerability, and clinical considerations\n related to this novel formulation.<\/jats:p>","DOI":"10.4140\/tcp.n.2023.300","type":"journal-article","created":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T08:47:56Z","timestamp":1688028476000},"page":"300-304","source":"Crossref","is-referenced-by-count":4,"title":["A Novel Formulation: Donepezil Patch"],"prefix":"10.4140","volume":"38","author":[{"given":"Megan","family":"Adelman","sequence":"first","affiliation":[{"name":"1 Cleveland Clinic Akron General, Center for Family Medicine, Akron, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lora","family":"Louis","sequence":"additional","affiliation":[{"name":"2 Northeast Ohio Medical University, Rootstown, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2625","reference":[{"issue":"2","key":"ref1","doi-asserted-by":"crossref","first-page":"111","DOI":"10.31887\/DCNS.2009.11.2\/cqiu","volume":"11","year":"2009","journal-title":". Dialogues Clin Neurosci."},{"key":"ref2","article-title":"Alzheimer\u2019s Association."},{"key":"ref3","doi-asserted-by":"crossref","first-page":"370","DOI":"10.7326\/0003-4819-148-5-200803040-00008","article-title":"Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians.","volume":"148","year":"2008","journal-title":"Ann Intern Med."},{"key":"ref4","first-page":"1","article-title":"Meta-analysis of randomized controlled trials on the efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer\u2019s disease.","volume":"13","year":"2019","journal-title":"Neuroscience."},{"issue":"3-4","key":"ref5","first-page":"131","article-title":"A systematic review and meta-analysis of the effectiveness of acetylcholinesterase inhibitors and memantine in treating the cognitive symptoms of dementia.","volume":"l45","year":"2018","journal-title":"Dement Geriatr Cogn Disord."},{"issue":"1","key":"ref6","first-page":"CD001190","article-title":"Donepezil for dementia due to Alzheimer\u2019s disease.","year":"2006","journal-title":"Cochrane Database Syst Rev."},{"issue":"3","key":"ref7","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1159\/000441894","article-title":"Donepezil adherence, persistence, and time to first discontinuation in a three-year follow-up of older people.","volume":"5","year":"2015","journal-title":"Dement Geriatr Cogn Dis Extra."},{"issue":"4","key":"ref8","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1017\/S1041610208007011","article-title":"Discontinuation of donepezil for the treatment of Alzheimer\u2019s disease in geriatric practice.","volume":"20","year":"2008","journal-title":"Int Psychogeriatr."},{"key":"ref9","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1111\/cns.13035","article-title":"A review of clinical treatment considerations of donepezil in severe Alzheimer\u2019s disease.","volume":"24","year":"2018","journal-title":"CNS Neurosci Ther."},{"issue":"3","key":"ref10","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1177\/2042098617750555","article-title":"An update on the safety of current therapies for Alzheimer\u2019s disease: focus on rivastigmine.","volume":"9","year":"2018","journal-title":"Ther Adv Drug Saf."},{"key":"ref11","year":"2022","journal-title":"Corium."},{"key":"ref12","first-page":"656","article-title":"Pharmacological evaluation and safety of a donepezil patch.","volume":"75","year":"2020","journal-title":"Pharmazie."},{"key":"ref13","first-page":"1419","article-title":"Single dose pharmacokinetics of the novel transdermal donepezil patch in healthy volunteers.","volume":"9","year":"2015","journal-title":"Drug Design Devel Ther."},{"key":"ref14","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ijpharm.2013.05.029","article-title":"A novel electronic skin patch for delivery and pharmacokinetic evaluation of donepezil following transdermal iontophoresis.","volume":"453","year":"2013","journal-title":"IntJ Pharm."},{"issue":"4","key":"ref15","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3988\/jcn.2022.18.4.428","article-title":"A Multinational, multicenter, randomized, double-blind, active comparator, phase III clinical trial to evaluate the efficacy and safety of donepezil transdermal patch in patients with Alzheimer\u2019s disease.","volume":"18","year":"2022","journal-title":"J Clin Neurol."},{"issue":"1","key":"ref16","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1755-5949.2009.00119.x","article-title":"Switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch.","volume":"16","year":"2010","journal-title":"CNS Neurosci Ther."},{"key":"ref17","article-title":"GoodRx"}],"container-title":["The Senior Care Pharmacist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ascp\/tscp\/2023\/00000038\/00000007\/art00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T14:28:12Z","timestamp":1688480892000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.4140\/TCP.n.2023.300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,1]]},"references-count":17,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7,1]]}},"alternative-id":["2639-9636(20230701)38:7L.300;1-"],"URL":"https:\/\/doi.org\/10.4140\/tcp.n.2023.300","relation":{},"ISSN":["2639-9636"],"issn-type":[{"value":"2639-9636","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,1]]}}}